Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reslizumab in Eosinophilic Asthma (OLE)
NCT01290887Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jun 2011
- Primary completion
- Jan 2015
- Modality
- Monoclonal Antibodies
- Countries
- 31
01
Overview
A Phase 3 trial of reslizumab in eosinophilic asthma (EA), sponsored by Teva Pharmaceutical Industries Ltd.. Started Jun 2011; status: terminated.
02
Drugs
reslizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT01290887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01290887.